IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est

IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745 billion vs $4.711 billion estimate.